Involvement of the adenosine A1 and A2A receptors in the antidepressant-like effect of zinc in the forced swimming test.
It was previously shown that the acute administration of zinc chloride elicits an antidepressant-like effect in the mouse forced swimming test (FST). We have also shown that the activation of adenosine A(1) and A(2A) receptors produces an antidepressant-like effect in FST. Thus, this study investigated the involvement of adenosine receptors in the antidepressant-like effect of zinc in the FST. The antidepressant-like effect of ZnCl(2) (30 mg/kg, i.p.) in the FST was prevented by the pretreatment of animals with caffeine (3 mg/kg, i.p., a non-selective adenosine receptor antagonist), DPCPX (2 mg/kg, i.p., a selective adenosine A(1) receptor antagonist) or ZM241385 (1 mg/kg, i.p., a selective adenosine A(2A) receptor antagonist), administered at doses that per se produced no anti-immobility effect. Moreover, the treatment of mice with CHA (0.05 mg/kg, i.p., a selective adenosine A(1) receptor agonist), DPMA (0.1 mg/kg, i.p., a selective adenosine A(2A) receptor agonist) or dipyridamole (0.1 microg/site, i.c.v., an adenosine transporter inhibitor) was able to potentiate the action of sub-effective doses of ZnCl(2). Taken together, the results suggest that the antidepressant-like effect of zinc in the mouse FST might involve a direct or indirect activation of adenosine A(1) and A(2A) receptors.
Lobato
Kelly R
KR
Departamento de Bioquímica, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina, Campus Universitário - Trindade - 88040-900, Florianópolis-SC, Brazil.
Binfaré
Ricardo W
RW
Budni
Josiane
J
Rosa
Angelo Oscar
AO
Santos
Adair Roberto S
AR
Rodrigues
Ana Lúcia S
AL
D000241:Adenosine / Q000031:analogs & derivatives / Q000494:pharmacology; D058907:Adenosine A1 Receptor Agonists; D058908:Adenosine A2 Receptor Agonists; D000814:Aniline Compounds / Q000494:pharmacology; D000818:Animals; D000928:Antidepressive Agents; D002110:Caffeine / Q000494:pharmacology; D000697:Central Nervous System Stimulants / Q000494:pharmacology; D004176:Dipyridamole / Q000494:pharmacology; D005260:Female; D008297:Male; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D033703:Nucleoside Transport Proteins / Q000037:antagonists & inhibitors; D043682:Receptor, Adenosine A1 / Q000187:drug effects*; D043705:Receptor, Adenosine A2A / Q000187:drug effects*; D013550:Swimming / Q000523:psychology*; D014227:Triazines / Q000494:pharmacology; D014230:Triazoles / Q000494:pharmacology; D014970:Xanthines / Q000494:pharmacology; D015032:Zinc / Q000494:pharmacology*
D058907:Adenosine A1 Receptor Agonists; D058908:Adenosine A2 Receptor Agonists; D000814:Aniline Compounds; D000928:Antidepressive Agents; D000697:Central Nervous System Stimulants; D033703:Nucleoside Transport Proteins; D043682:Receptor, Adenosine A1; D043705:Receptor, Adenosine A2A; D014227:Triazines; D014230:Triazoles; D014970:Xanthines; C097270:ZM 241385; C444719:adenosine transporter; C027513:N(6)-cyclohexyladenosine; D002110:Caffeine; D004176:Dipyridamole; C050795:N,N-dimethyl-4-anisidine; C051360:1,3-dipropyl-8-cyclopentylxanthine; D015032:Zinc; D000241:Adenosine